247 related articles for article (PubMed ID: 33203445)
21. Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy.
González-Duarte A; Lem-Carrillo M; Cárdenas-Soto K
Amyloid; 2013 Dec; 20(4):221-5. PubMed ID: 24053266
[TBL] [Abstract][Full Text] [Related]
22. Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation.
Bonilauri B; Shin HS; Htet M; Yan CD; Witteles RM; Sallam K; Wu JC
Stem Cell Res; 2023 Oct; 72():103215. PubMed ID: 37788558
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
[TBL] [Abstract][Full Text] [Related]
24. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients.
Luigetti M; Conte A; Del Grande A; Bisogni G; Madia F; Lo Monaco M; Laurenti L; Obici L; Merlini G; Sabatelli M
Neurol Sci; 2013 Jul; 34(7):1057-63. PubMed ID: 22592564
[TBL] [Abstract][Full Text] [Related]
25. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
26. Hereditary Transthyretin Amyloidosis in Eight Chinese Families.
Meng LC; Lyu H; Zhang W; Liu J; Wang ZX; Yuan Y
Chin Med J (Engl); 2015 Nov; 128(21):2902-5. PubMed ID: 26521788
[TBL] [Abstract][Full Text] [Related]
27. Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration.
Ibrahim RB; Yeh SY; Lin KP; Ricardo F; Yu TY; Chan CC; Tsai JW; Liu YT
Cell Mol Life Sci; 2020 Apr; 77(7):1421-1434. PubMed ID: 31728576
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
[TBL] [Abstract][Full Text] [Related]
29. Hereditary transthyretin-related amyloidosis.
Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
[TBL] [Abstract][Full Text] [Related]
30. Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update.
Monda E; Cirillo C; Verrillo F; Palmiero G; Falco L; Aimo A; Emdin M; Merlo M; Limongelli G
Heart Fail Clin; 2024 Jul; 20(3):317-323. PubMed ID: 38844302
[TBL] [Abstract][Full Text] [Related]
31. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
Nie T; Heo YA; Shirley M
Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
[TBL] [Abstract][Full Text] [Related]
32. Late-onset familial amyloid polyneuropathy (FAP) Val30Met without family history.
Rudolph T; Kurz MW; Farbu E
Clin Med Res; 2008 Sep; 6(2):80-2. PubMed ID: 18606975
[TBL] [Abstract][Full Text] [Related]
33. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
34. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.
Tini G; Vianello PF; Gemelli C; Grandis M; Canepa M
J Cardiovasc Transl Res; 2019 Dec; 12(6):514-516. PubMed ID: 30604309
[TBL] [Abstract][Full Text] [Related]
35. Familial amyloidosis with polyneuropathy type 1 caused by transthyretin mutation Val50Met (Val30Met): 4 cases in a non-endemic area.
Andrés N; Poza JJ; Martí Massó JF
Neurologia (Engl Ed); 2018; 33(9):583-589. PubMed ID: 27793437
[TBL] [Abstract][Full Text] [Related]
36. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K
Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236
[TBL] [Abstract][Full Text] [Related]
37. A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.
Olsson M; Norgren N; Obayashi K; Plante-Bordeneuve V; Suhr OB; Cederquist K; Jonasson J
BMC Med Genet; 2010 Sep; 11():130. PubMed ID: 20840742
[TBL] [Abstract][Full Text] [Related]
38. Amyloid heart disease mimicking hypertrophic cardiomyopathy.
Mörner S; Hellman U; Suhr OB; Kazzam E; Waldenström A
J Intern Med; 2005 Sep; 258(3):225-30. PubMed ID: 16115295
[TBL] [Abstract][Full Text] [Related]
39. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
Gopal DM; Ruberg FL; Siddiqi OK
Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
[TBL] [Abstract][Full Text] [Related]
40. A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.
Jimenez-Zepeda VH; Bahlis NJ; Gilbertson J; Rendell N; Porcari R; Lachmann HJ; Gillmore JD; Hawkins PN; Rowczenio DM
Amyloid; 2015 Mar; 22(1):26-30. PubMed ID: 25430583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]